U.S.-based Lilly and Danish rival Novo Nordisk are in a race to get their obesity drugs approved to treat other ailments. Novo's Wegovy was approved as a treatment for heart disease in March, while Lilly's own heart-disease trial for Zepbound is expected to conclude this year.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/PktehH1
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment